#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2566	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2040	230.7	0	.	n	.	0	G1207A	SNP	1207	1207	G	1529	1529	A	301	A	185	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2566	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2040	230.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1772	1772	T	227	T,C	142,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2566	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2040	230.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1506	1506	C	289	C	181	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4888	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3653	244.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1753	1753	A	277	A	172	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4888	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3653	244.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2387	2387	C	287	C	175	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4888	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3653	244.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2461	2461	A	285	A	176	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4888	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3653	244.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3013	3013	C	287	C	168	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	140	folP	852	852	99.77	folP.l15.c4.ctg.1	1303	19.7	0	.	p	.	0	D71H	NONSYN	211	213	GAT	304	306	CAT	13;13;13	C;A;T	6;7;6	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	140	folP	852	852	99.77	folP.l15.c4.ctg.1	1303	19.7	0	.	p	.	0	A204V	NONSYN	610	612	GCA	703	705	GTA	29;29;29	G;T;A	20;20;20	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	140	folP	852	852	99.77	folP.l15.c4.ctg.1	1303	19.7	1	SNP	p	R228S	0	.	.	682	684	CGC	775	777	CGC	31;31;31	C;G;C	20;21;20	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	370	gyrA	2751	2291	99.78	gyrA.l6.c4.ctg.1	2397	25.6	0	.	p	.	0	M250I	NONSYN	748	750	ATG	854	856	ATA	18;18;17	A;T;A	10;10;9	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	370	gyrA	2751	2291	99.78	gyrA.l6.c4.ctg.1	2397	25.6	1	SNP	p	S91F	0	.	.	271	273	TCC	377	379	TCC	38;41;41	T;C;C	22;23;25	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	370	gyrA	2751	2291	99.78	gyrA.l6.c4.ctg.1	2397	25.6	1	SNP	p	D95N	0	.	.	283	285	GAC	389	391	GAC	42;43;43	G;A;C	25;25;24	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	370	gyrA	2751	2291	99.78	gyrA.l6.c4.ctg.1	2397	25.6	1	SNP	p	D95G	0	.	.	283	285	GAC	389	391	GAC	42;43;43	G;A;C	25;25;24	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	370	gyrA	2751	276	100.0	gyrA.l6.c4.ctg.2	472	15.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	531	82	mtrR	633	550	99.64	mtrR.l15.c4.ctg.1	781	16.5	0	.	p	.	0	D171G	NONSYN	511	513	GAC	742	744	GGC	8;7;9	G;G,A;C	5;0,3;3	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	80	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	755	18.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1458	1460	GCA	25;27;27	G;C;A	15;14;14	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	1	SNP	p	D86N	0	.	.	256	258	GAC	411	413	GAC	52;52;53	G;A;C	31;30;32	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	1	SNP	p	S87R	0	.	.	259	261	AGT	414	416	AGT	52;52;51	A,C;G;T	27,1;31;29	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	1	SNP	p	S87W	0	.	.	259	261	AGT	414	416	AGT	52;52;51	A,C;G;T	27,1;31;29	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	1	SNP	p	S87I	0	.	.	259	261	AGT	414	416	AGT	52;52;51	A,C;G;T	27,1;31;29	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	472	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2724	31.0	1	SNP	p	S88P	0	.	.	262	264	TCC	417	419	TCC	51;52;52	T;C;C	31;28;30	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	296	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2416	22.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1347	1349	GGC	13;13;13	G;G;C	8;8;7	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1187	1189	GCA	41;41;43	G;C;A	25;24;25	penA.1.003:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1190	1192	ATC	42;42;42	A;T;C	25;25;25	penA.1.003:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1202	1204	GTG	43;43;43	G;T;G	25;24;24	penA.1.003:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1202	1204	GTG	43;43;43	G;T;G	25;24;24	penA.1.003:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1706	1708	ACC	11;11;10	A;C;C	7;8;8	penA.1.003:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1760	1762	GCG	4;4;4	G;C;G	4;4;2	penA.1.003:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1760	1762	GCG	4;4;4	G;C;G	4;4;2	penA.1.003:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1883	1885	GGC	16;16;16	G;G;C	11;11;9	penA.1.003:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1892	1894	GGC	15;15;15	G;G;C	11;10;9	penA.1.003:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.003	penA.1.003	1	1	27	332	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2089	27.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1910	1912	CCG	13;13;13	C;C;G	8;8;8	penA.1.003:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	632	ponA	2397	201	100.0	ponA.l15.c4.ctg.1	484	15.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	632	ponA	2397	2397	99.92	ponA.l15.c4.ctg.2	2644	36.3	0	.	p	.	0	A621T	NONSYN	1861	1863	GCC	2090	2092	ACC	52;52;52	A;C;C	27;30;31	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	783	632	ponA	2397	225	100.0	ponA.l15.c4.ctg.3	469	6.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	168	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1405	20.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	285	285	C	7	C	4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	T18M	NONSYN	52	54	ACG	485	487	ATG	32;32;32	A;T;G	22;19;19	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	860	862	CAA	44;50;50	C;A;A	30;33;32	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1067	1069	GAT	74;74;74	G;A;T	51;49;47	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1070	1072	GGT	74;74;74	G;G;T	47;53;50	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1076	1078	GCT	75;76;76	G;C;T	50;50;53	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	S220T	NONSYN	658	660	AGC	1091	1093	ACT	67;67;67	A;C;T	40;43;39	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	R257M	NONSYN	769	771	AGG	1202	1204	ATG	47;46;47	A;T;G	29;29;30	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	R258S	NONSYN	772	774	AGG	1205	1207	AGC	47;46;46	A;G;C,A	29;29;29,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	A259G	NONSYN	775	777	GCT	1208	1210	GGT	46;46;45	G;G;T	29;29;27	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1322	1324	AAC	34;35;34	A;A;C	21;18;20	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	304	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1668	33.0	1	SNP	p	G120K	0	.	.	358	360	GGC	791	793	GGC	37;39;41	G;G;C	26;26;29	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1114	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4824	43.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1854	1856	CAT	51;51;50	C;A;T	33;33;32	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	539	104	rpsJ	312	312	99.68	rpsJ.l15.c4.ctg.1	1080	20.4	0	.	p	.	0	R62C	NONSYN	184	186	CGT	560	562	TGT	32;32;32	T;G;T	20;22;20	.	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	539	104	rpsJ	312	312	99.68	rpsJ.l15.c4.ctg.1	1080	20.4	1	SNP	p	V57M	0	.	.	169	171	GTG	545	547	GTG	34;34;34	G;T;G	24;23;24	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
